Abstract 2676
Background
Oncology nurses are responsible to provide their patients with the evidence-based care. Clinical guidelines or recommendations can be developed by scientific associations as a guide for performing evidence-based practice. These guidelines are often taken into consideration for the assessment of professional responsibility, as well as to guide the practice. The Italian Institute of Health identified the Italian Association of Cancer Nurses (AIIAO) among the scientific societies authorised to produce, adapt and implement guidelines. However, it is important to identify which areas of oncology nursing warrant an action to facilitate AIIAO in setting the agenda. A specific prerequisite for developing high-quality guidelines is incorporating nurses’ views into priority-setting. The aim of this study is to use a bottom-up approach to empirically investigate which areas of oncology nursing require higher priority in the definition of evidence-based recommendations.
Methods
This is a multi-phase study including a cross-sectional national survey. In order to develop the tool for the survey, a systematic search of the literature, a focus group, and content and face validity evaluation will be conducted.
Results
Seven areas were identified by the literature review to develop the survey: (a) fatigue; (b) pain; (c) sleep disorders; (d) secondary symptoms; (e) cognitive impairment resulting from cancer and its treatment; (f) chemotherapy-induced peripheral neuropathy; and (g) psychological distress. This research is still ongoing. A panel of researchers are operationalising the identified areas in the items for the national survey. Cancer nurses will be asked to rate the priority of each area for the implementation, adaptation and development of AIIAO clinical guidelines.
Conclusions
The results of this survey might raise awareness about oncology nurses’ opinions on which areas of clinical practice warrant an action. This will facilitate the associations and affiliated working groups in developing evidence-based recommendations. Moreover, a bottom-up mapping of the nurses’ priorities will inform the planning of AIIAO strategic activities targeted to strengthen cancer care.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Italian Association of Cancer Nurses (AIIAO).
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5603 - Development of a comprehensive next-generation targeted sequencing assay for detection of gene-fusions in solid tumors
Presenter: Vinay Mittal
Session: Poster Display session 3
Resources:
Abstract
4952 - Next-generation sequencing for better treatment strategy of cancer of unknown primary (CUP)
Presenter: Kang Kook Lee
Session: Poster Display session 3
Resources:
Abstract
4590 - Circulating-free DNA analysis from long-term surviving metastatic colorectal cancer patients undergoing surgery for resectable disease.
Presenter: Michele Ghidini
Session: Poster Display session 3
Resources:
Abstract
3696 - Ultra-sensitive detection of circulating tumor DNA identifies patients in high risk of recurrence in early stages melanoma
Presenter: Filip Janku
Session: Poster Display session 3
Resources:
Abstract
4295 - Identification of the founder BRCA1 mutation c.4117G>T (p.Glu1373*) recurring in Abruzzo and Lazio regions of Central Italy and predisposing to breast/ovarian and BRCA1-related cancers
Presenter: Daniela Di Giacomo
Session: Poster Display session 3
Resources:
Abstract
2214 - Enzalutamide (ENZA) and Apalutamide (APA) In vitro chemical reactivity studies and Activity in a Mouse Drug Allergy Model (MDAM)
Presenter: Mausumee Guha
Session: Poster Display session 3
Resources:
Abstract
5044 - Influence of genetic variation in COMT on cisplatin-induced nephrotoxicity in cancer patients.
Presenter: Bram Agema
Session: Poster Display session 3
Resources:
Abstract
3293 - Cardioprotective and anti-inflammatory effects of Empagliflozin during treatment with Doxorubicin: a cellular and preclinical study
Presenter: Vincenzo Quagliariello
Session: Poster Display session 3
Resources:
Abstract
3324 - Breast Cancer Organoids Model Treatment Response of HER2 Targeted Therapy in HER2-mutant Breast Cancer
Presenter: Xuelu Li
Session: Poster Display session 3
Resources:
Abstract
2115 - Preclinical in vivo screening to predict responder patients depend on EGFR status
Presenter: Yejin Kim
Session: Poster Display session 3
Resources:
Abstract